Clinical Trial Update: Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

View source ↗

Summary

This completed clinical trial investigates optimal platelet inhibition for patients undergoing percutaneous coronary intervention, using dual antiplatelet thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Aspirin (Aspirin)
• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Percutaneous Coronary Intervention, Dual Antiplatelet Therapy | Status: COMPLETED